Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pinning Hopes On A Wider Offering, Boehringer-Lilly Launch DPP-4 Trajenta In A Crowded India Market

This article was originally published in PharmAsia News

Executive Summary

A 30% annual growth in the anti-diabetes market is fueling new launches in India, but competition is getting tougher.


Related Content

Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts